Hi pivade
Yes, yes, yes.
I tried to make this point earlier. Note from my previous post (on 21/2/24)...
Note: This trial is looking at all the key markers that Big Pharma will want to see. These include, but are not limited to:1. change in iron content
2. change in aggregating alpha-Synuclein levels (this is the one I’m particularly waiting to see)
3. change in Neurofilament Light Chain Levels
I stated then that 'changes in alpha-Synuclein levels' are the ones I'm wait for ... if we get these, then we are on the money.
It's that simple. This message is for BIG PHARMA. This is what I want to see, and I would hope it is what BP are looking for also.
As always, opinion only.
Ann: Alterity to Present New Data at the AAN 2024 Annual Meeting, page-12
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $32.63K | 10.83M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 21801548 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130971725 | 28 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |